AI in Neurology Market Size, Share, and Industry Analysis, By Component (Hardware/ Devices and Software & Services), By Deployment (Cloud-Based, On Premise, and Hybrid), By Disease Indication (Multiple Sclerosis, Dementia and Alzheimer's, Epilepsy, Parkinson's disease, Brain tumors, and Others ), By Technology (Machine, Workflow & Care Coordination, Neuromodulation & Rehabilitation, Surgical Planning, and Others), By End User (Hospitals & ASCs, Neurospecialty Clinics, Neuroradiology Diagnostic Centres, and Others), and Regional Forecast 2026-2034

The AI in neurology market size was valued at USD 0.69 billion in 2025. The market is projected to grow from USD 0.82 billion in 2026 to USD 3.54 billion by 2034, exhibiting a CAGR of 20.15% during the forecast period.

The AI in neurology market is estimated to grow significantly over the forecast period, driven by the increasing adoption of AI tools to analyze complex datasets. It enables earlier detection of such diseases, optimizes treatment plans using personalized data, reduces clinician workload, and enables rapid, automated neuroimaging analysis. Clinicians increasingly need advanced neurology-focused solutions to manage vast datasets.

Additionally, innovative product launches by key companies integrating advanced technologies determine the market's growth potential.

• For instance, in May 2025, Natus Medical launched BrainWatch, a point-of-care EEG solution driven by AI. The solution brought the reliability and trust expected from the world's largest neurodiagnostic company into critical care environments. The launch addresses the needs of customers seeking a point-of-care solution that integrates with NeuroWorks, an EEG platform used worldwide. Such developments boost market growth.

Furthermore, funding initiatives, technological advancements, and key mergers and partnerships by major companies strengthen their market position and support the overall market growth.

AI in Neurology Market Driver

Rising Neurology Caseloads and Specialist Capacity Constraints Accelerate Demand for AI-Enabled Triage and Care Coordination, Driving Market Growth.

One of the principal factors driving AI growth in neurology is the rising neurology caseload. With significant specialist capacity restraint, the need for these smart solutions to reduce workload increases. Neurology departments are witnessing higher patient volumes from stroke, dementia, and other chronic neurological conditions, while the number of available specialist teams is not scaling at the same pace. This disparity creates delays in workflows, with limited manpower for reading scans, escalating urgent cases, and coordinating transfers. As caseload pressure rises, hospitals adopt AI to automate repetitive tasks, such as flagging suspected cases, prioritizing worklists, and routing patients more quickly to the right clinician and facility. This directly improves operational throughput and supports consistent decision-making.

Key companies are focusing on strategic collaborations and product launches to monetize these growth opportunities and improve patient care.

• For instance, in February 2025, Viz.ai announced new clinical evidence on the impact of its AI-powered stroke solution, highlighting improvements in treatment times and hospital economics—supporting the role of AI in handling growing neuro caseloads and coordination demands.

Download Free sample to learn more about this report.

For instance, in October 2025, the WHO published a global status report on neurology that stated that 42% of the worldwide population experienced some health loss due to neurological disorders in 2021. Among these, the Southeast Asia region had the highest number of patients. The high prevalence of neurological disorders is driving demand for AI in neurology.

AI in Neurology Market Restraint

Unclear Reimbursement And Inconsistent Payment Pathways Limiting ROI For Neurology AI Deployments And Limiting Market Growth

A key factor adversely impacting market growth is the complex reimbursement landscape and inconsistent pathways. When payers do not provide a clear, consistent way to reimburse AI-enabled neurology workflows, hospitals struggle to justify and scale these tools beyond pilots. Vendors rely on hospital budgets or short-term innovation funds, leading procurement teams to push back due to uncertain payback. These factors collectively lead to fragmented adoption across sites and slow adoption.

• For instance, in 2022, an npj Digital Medicine editorial reported that the reimbursement of medical AI serves as a primary gatekeeper to mass clinical adoption, highlighting how a lack of sustainable reimbursement pathways can constrain implementation at scale.

AI in Neurology Market Opportunity

Scaling Neurocritical Monitoring with Real-Time AI Alerting Offers a Lucrative Growth Opportunity

In neuro-ICUs and emergency settings, many neurological events, such as non-convulsive seizures, are time-critical and can be easily missed in the absence of continuous monitoring and specialist interpretation. When hospitals face limited neurophysiology coverage, particularly after hours, patients can wait longer for EEG review, delaying treatment and worsening outcomes. Real-time AI alerting helps by continuously analyzing bedside signals, quickly flagging high-risk patterns, and guiding clinicians to escalate care sooner. This creates a clear growth opportunity as more hospitals can expand neurocritical monitoring capacity, making adoption easier to justify and scale. These factors also generate revenue for healthcare providers.

Underscoring these critical applications, key companies are focusing on novel product launches, simultaneously seeking regulatory approval to capitalize on the growth potential.  

• For instance, in November 2025, Ceribell received 510(k) approval for its Clarity algorithm from the U.S. FDA. Positioned to enable rapid bedside detection and support timely treatment decisions—supporting the push toward real-time AI alerting in neurocritical monitoring.

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Advancements in AI in Neurology
• Prevalence of Key Diseases, By Key Regions, 2025
• Key Industry Developments (Strategic Partnerships, Collaborations, Acquisitions, and Mergers)
• New Product Launches, By Key Players
• Key Start Ups, By Key Regions

Analysis by Component

Based on the component, the global AI in neurology market is segmented into hardware/ devices and software & services.

Among these, software & services dominated the market. It accounts for significant value creation for consumers, as this software can be deployed across scanners, PACS/EHR systems, and multiple sites to automate detection, quantify disease progression, and coordinate care. As hospitals scale neurology pathways, software is the fastest way to improve speed, standardization, and throughput. Additionally, innovative software launches and updates from key companies, as well as strategic acquisitions to expand the portfolio, reinforce segment dominance.  

• For instance, in September 2025, GE HealthCare acquired iCometrix to strengthen its neurology portfolio with brain MRI assessment solutions. The development showcased how software platforms are central to neurology AI strategy and revenue. Such developments are expected to lead to segmental growth.

Analysis by Deployment

Based on deployment, the global AI in neurology market is segmented into cloud-based, on-premise, and hybrid.

Among these, cloud-based deployment was the predominant deployment model in the market. Neurology care often depends on rapid collaboration, including the sharing of images, the escalation of suspected cases, and the support of decisions across networks. Cloud deployment reduces the friction of multi-site rollout, making updates and algorithm improvements easier. These deployments also enable faster expansion to smaller hospitals. As health systems prioritize speed and scalability, cloud models typically dominate in procurement decisions for network-wide neurology AI. Highlighting these advantages, key companies are launching new products and participating in strategic collaborations to expand their offerings in the segment. 

• For instance, in November 2025, Nicolab partnered with the Harrison.ai Open Platform to make StrokeViewer available. The partnership aimed to remove platform and integration barriers and speed access for hospitals, supporting cloud-style scale-out and reinforcing segments' dominance.

Analysis by Disease Indication

Based on disease indication, the market is divided into multiple sclerosis, dementia and alzheimer's, epilepsy, parkinson's disease, brain tumors, and others.

Brain tumours are projected to account for a leading share of the market. The market is projected to be dominated by these technologies. Wise applications of AI in neurology, such as navigation assistance, image enhancement, tom synthesis/3D reconstruction, and confirmation support, depend on models trained on large imaging datasets to improve accuracy and robustness. These systems handle variability in anatomy, breathing motion, and image quality, making ML/DL a crucial component behind computer vision outputs. Underscoring its essential applications, the technology is anticipated to dominate. Additionally, continuous upgrades and new product launches, particularly in this segment, reinforce robust growth. 

• For instance, in August 2025, Body Vision Medical announced a major LungVision platform upgrade that expanded access to AI Tomo, highlighting AI-driven image reconstruction used in bronchoscopy workflows. Such developments are expected to drive the segmental growth.

Analysis by Technology

Based on technology, the market is divided into machine learning  & deep learning, natural language processing (NLP), and others.

The machine learning and deep learning segment is projected to dominate the market. Most neurology AI use cases are pattern-recognition problems across imaging and biosignals, where deep learning is used for detection, segmentation, and real-time classification. As hospitals demand higher accuracy and faster alerts with fewer false positives, vendors prioritize ML/DL architectures that can generalize across datasets and support regulated clinical claims. Additionally, continuous upgrades and new product launches, as well as regulatory approvals, particularly in this segment, reinforce segmental growth.  

• For instance, in November 2025, RapidAI received clearance from the U.S. FDA for five new imaging modules (Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement), highlighting continued expansion of deep clinical AI capabilities used in acute care imaging workflows. Such developments are expected to drive the segmental growth.

Analysis by Application

In terms of application, , the market is divided into screening & diagnosis, clinical decision support, workflow & care coordination, neuromodulation & rehabilitation, surgical planning, and others.

The workflow & care coordination segment is estimated to dominate the market. They deliver the fastest ROI in neurology and play a crucial role in reducing delays, triaging urgent cases, alerting teams, and coordinating transfers. These advantages enable hospitals to quickly measure time savings and throughput improvements. When caseloads rise and specialist availability varies, care coordination platforms help ensure the right patient reaches the right clinician or center more quickly, thereby increasing adoption across stroke networks and large health systems. To meet this high demand and ensure prompt patient care, key companies are directing their resources toward research and development to support these care coordination applications. 

• For instance, in December 2024, Viz.ai integrated Avicenna.AI tools into the Viz.ai One platform to advance neurovascular workflows. The development highlights vendors expanding coordination platforms with more capabilities. Such developments are expected to drive the segmental growth.

Analysis by End User

By end user, the market is divided into hospitals & ASCs, neurospecialty clinics, neuroradiology diagnostic centres, and others.

Hospitals and ASCs are estimated to account for a leading market share. Most neurology AI is operationalized at a large scale in these healthcare settings. They provide robust infrastructure that enables imaging, monitoring, and intervention workflows. As hospitals are accountable for outcomes and time-to-treatment metrics, they adopt AI to standardize protocols, reduce holdups, and support decision-making. Furthermore, strategic collaboration among these solution providers and hospitals drives growth in the segment.   

• For instance, in April 2025, RapidAI collaborated with Tift Regional Medical Center, where they adopted its platform to accelerate stroke decision-making. Such developments are expected to drive segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0 % of the global AI in neurology market in 2025. North America is witnessing robust growth, with rising disease prevalence and increasing healthcare expenditure. Various reimbursement initiatives are also being carried out that strengthen the adoption of these technologies in the region. Additionally, there is constant pressure on healthcare providers to reduce diagnostic timelines, further deepening the need for these AI solutions. As more sites standardize protocols and measure turnaround times, AI becomes a practical way to improve throughput and consistency. This accelerates multi-site deployments and renewals as benefits are realized quickly in operations and clinical workflows.

Underscoring these factors, key companies are focusing on new product launches, which are fueling growth in the region.

• For instance, in January 2024, Brainomix received clearance for Brainomix 360 Triage Stroke from the U.S. FDA, enabling real-time alerts for suspected LVO/ICH from non-contrast CT—supporting scale-up of AI triage in U.S. stroke workflows. Such developments drive the market growth in the region.

Europe is expected to grow at a significant CAGR during the forecast period. The region is experiencing growth as several countries are focusing on stroke and neuro pathways and highlighting the ever-increasing need for AI tools to support diagnostic decision-making in neurology. The region is also experiencing increasing funding initiatives to highlight regional growth. As health systems validate impact at scale, adoption expands beyond pilots into broader stroke-network rollouts.

• For instance, in May 2024, Brainomix highlighted data showing that its Brainomix 360 AI improved acute stroke pathway performance in England/NHS settings, reinforcing momentum for AI decision support across European stroke care and thereby fueling market growth.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region is facing a rising burden from stroke and neurodegenerative disease, driving the demand for AI in neurology to manage a large amount of data and rapid diagnosis. These solutions can scale expert-level interpretation and monitoring to more hospitals, support consistent protocols, and help clinicians act sooner. As Asia Pacific-based biotech and pharma pipelines expand in neurology, AI also gains traction, strengthening regional growth.

• For instance, in December 2025, Brainomix partnered with Argenica Therapeutics (Australia) to use AI imaging biomarkers to evaluate a neuroprotective drug candidate in acute ischemic stroke—showing expanding Asia Pacific -linked investment and collaboration around AI-enabled neurology evidence generation. Such developments are driving the region's growth.

Key Players covered

The global AI in neurology market is consolidated, with a few players capturing a significant market share.

The report includes the profiles of the following key players.

• ai, Inc. (U.S.)
• Icometrix (U.S.)
• Neurotechnology (U.S.)
• RapidAI, Inc. (U.S.)
• BRAINOMIX LIMITED (U.K.)
• NICo-Lab B.V. (The Netherlands)
• CeriBell, Inc. (U.S.)
• NeuroPace, Inc. (Germany)
• PERSYST DEVELOPMENT CORPORATION (Ireland)
• Medtronic plc (U.S.)

Key Industry Developments

• December 2025: Aidoc partnered with Cercare Medical and Circle CVI to expand its neurosciences portfolio with advanced MR Perfusion and automated ASPECTS (Alberta Stroke Program Early CT Score), for stroke and complex neuro care. These partnerships connected fragmented neuro workflows and accelerate high–stakes decisions.
• November 2025: Koninklijke Philips N.V. partnered with Cortechs.ai to advance quantitative neuroimaging and strengthen leadership in precision diagnostics in neurology. The collaboration transformed how neurological diseases are detected, monitored, and managed.